Core Viewpoint - Quoin Pharmaceuticals Ltd. is set to provide an operational update on November 6, 2025, detailing key achievements and financial highlights for Q3 2025 [1]. Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases [2]. - The company aims to address unmet medical needs for patients and their communities [2]. - Quoin's pipeline includes four products in development targeting various rare and orphan indications such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa [2].